Entry into a Material Definitive Agreement

Business Context and Reporting Period

Company: Galecto, Inc. (Nasdaq: GLTO)
Reporting Date: November 10, 2025
Event: Completion of a business combination with Damora Therapeutics, Inc. ("Damora") and a concurrent private placement financing.

On November 10, 2025, Galecto, Inc. acquired Damora Therapeutics, Inc. via a tax-free reorganization. Damora became a wholly-owned subsidiary of Galecto. The transaction was structured through two merger entities: Daylight Merger Sub I, Inc. and Daylight Merger Sub II, LLC.

Key Financial Metrics and Transaction Terms

Financing (PIPE):

  • Amount Raised: Approximately $285 million.
  • Securities Issued: 39,641 shares of Series C Non-Voting Convertible Preferred Stock.
  • Conversion: Each share converts into 1,000 shares of Common Stock.
  • Closing Date: Expected November 12, 2025.

Merger Consideration to Damora Stockholders:

  • Common Stock: 265,309 shares of Galecto Common Stock.
  • Series B Preferred Stock: 16,366 shares (convertible into 1,000 Common Stock shares each).
  • Series C Preferred Stock: 4,241 shares (convertible into 1,000 Common Stock shares each).

Financial Statements: This Form 8-K does not provide revenue, profit, cash flow, margin, or debt metrics for either company. The filing focuses on the transaction structure and capitalization changes.

Material Changes and Corporate Actions

Board of Directors Changes:

  • Resignations: Anne Prener, M.D., David Shapiro, M.D., and Amy Wechsler, M.D. resigned immediately prior to the merger effective time.
  • Appointments: Peter Harwin, Chris Cain, Ph.D., and Julianne Bruno were appointed to the Board immediately following the merger.

Executive Compensation Changes:

  • Lori Firmani: Appointed Chief Financial Officer (previously interim). Base salary increased from $300,000 to $375,000.
  • Retention Bonuses: Approved for CEO Hans Schambye, CFO Lori Firmani, and General Counsel Garrett Winslow. Bonuses equal 100% of target bonus payable by April 30, 2026, or upon termination without Cause.
  • Target Bonus Amounts: Dr. Schambye (DKK 2,173,800), Ms. Firmani ($112,500), Mr. Winslow ($161,160).

Stockholder Proposals: The Company will hold a stockholders' meeting to approve: (i) conversion of Series B and C Preferred Stock to Common Stock; (ii) redomicile of the Company; and (iii) potential charter amendments or reverse stock splits to maintain Nasdaq listing standards.

Outlook, Risks, and Contingencies

Lock-Up Agreements: Certain Damora stockholders and Company directors/officers are subject to a 180-day lock-up on the sale or transfer of shares held at closing.

Registration Rights: The Company must file a resale registration statement within 45 days of the financing closing and use commercially reasonable efforts to have it declared effective within 5 business days of no-review notice (or 60 days if reviewed).

Risk Factors: The filing includes standard forward-looking statement disclaimers. Risks include the failure to obtain stockholder approval for the conversion proposals, delays in the financing closing, and general uncertainties regarding future clinical results and business strategies.

Investor Verification Checklist

  • Financing Closing: Verify the actual closing of the $285 million PIPE financing on or around November 12, 2025.
  • Stockholder Approval: Monitor the outcome of the upcoming stockholders' meeting regarding the conversion of Preferred Stock and the Redomicile Proposal.
  • Nasdaq Compliance: Confirm whether a reverse stock split is required and approved to maintain listing standards post-transaction.
  • Capitalization: Review the final post-transaction capitalization table, specifically the dilution impact of the 39,641 Series C shares (39.6M common equivalent) and the merger consideration.
  • Board Composition: Confirm the new Board's oversight of the combined entity's strategic direction.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.